Haleon PLC Sponsored ADR (NYSE:HLN) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Haleon has a consensus “Moderate Buy” rating from 10 analysts, comprising two sells, three holds, three buys, and two strong buys. Recent recommendations were mixed, with some firms upgrading the stock while others downgraded or maintained neutral views.
• Shares opened at $10.03, with a market capitalization of approximately $44.16 billion and a 52-week trading range of $8.65 to $11.28. The stock trades at a P/E ratio of 25.71.
• Haleon declared a quarterly dividend of $0.0642 per share, payable September 17 to shareholders of record August 14; the company’s dividend payout ratio is 64.1%.

Shares of Haleon PLC Sponsored ADR (NYSE:HLN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, three have assigned a buy recommendation and two have given a strong buy recommendation to the company.

Several analysts have issued reports on the company. Wall Street Zen raised Haleon from a "hold" rating to a "buy" rating in a research note on Sunday, July 12th. Morgan Stanley restated an "overweight" rating on shares of Haleon in a report on Thursday. Zacks Research lowered shares of Haleon from a "hold" rating to a "strong sell" rating in a report on Tuesday, July 21st. Rothschild & Co Redburn cut shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, June 16th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Haleon in a report on Tuesday, June 30th.

Haleon Stock Performance

Shares of NYSE HLN opened at $10.03 on Friday. The stock has a market cap of $44.16 billion, a price-to-earnings ratio of 25.71, a P/E/G ratio of 2.01 and a beta of 0.12. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. Haleon has a 1-year low of $8.65 and a 1-year high of $11.28. The stock's 50-day moving average is $9.51 and its 200 day moving average is $9.85.

Haleon Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Thursday, September 17th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.0642 per share. This represents a dividend yield of 127.0%. The ex-dividend date of this dividend is Friday, August 14th. Haleon's dividend payout ratio (DPR) is 64.10%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Morgan Stanley boosted its holdings in Haleon by 16.0% during the 4th quarter. Morgan Stanley now owns 21,495,383 shares of the company's stock valued at $217,318,000 after acquiring an additional 2,962,856 shares during the period. Norges Bank bought a new position in Haleon during the 4th quarter worth approximately $163,529,000. Arrowstreet Capital Limited Partnership increased its stake in Haleon by 82.8% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company's stock worth $146,892,000 after purchasing an additional 6,647,329 shares during the period. Bank of America Corp DE increased its stake in Haleon by 116.7% in the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company's stock worth $128,423,000 after purchasing an additional 6,669,923 shares during the period. Finally, Sculptor Capital LP lifted its position in Haleon by 5.1% in the fourth quarter. Sculptor Capital LP now owns 10,454,868 shares of the company's stock valued at $105,699,000 after purchasing an additional 505,000 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.

About Haleon

Haleon plc NYSE: HLN is a global consumer healthcare company formed through the separation of a large pharmaceutical group's consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source